Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011010969 - CANCER BIOMARKER AND THE USE THEREOF

Publication Number WO/2011/010969
Publication Date 27.01.2011
International Application No. PCT/SG2010/000280
International Filing Date 23.07.2010
Chapter 2 Demand Filed 19.05.2011
IPC
G01N 33/52 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
G01N 33/574 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
G01N 2333/4716
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
46from vertebrates
47Assays involving proteins of known structure or function as defined in the subgroups
4701Details
4716Complement proteins, e.g. anaphylatoxin, C3a, C5a
G01N 33/57446
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57407Specifically defined cancers
57446of stomach or intestine
Applicants
  • NATIONAL UNIVERSITY OF SINGAPORE [SG]/[SG] (AllExceptUS)
  • LIM, Yoon Pin [SG]/[SG] (UsOnly)
Inventors
  • LIM, Yoon Pin
Agents
  • YU SARN AUDREY & PARTNERS
Priority Data
200904976-823.07.2009SG
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CANCER BIOMARKER AND THE USE THEREOF
(FR) BIOMARQUEUR DU CANCER ET SON UTILISATION
Abstract
(EN)
Gastric cancer is one of the leading causes of cancer-related death worldwide. To date no specific marker is available for gastric cancer screening. The expression profile of 37 proteins was identified to be consistently different between the plasma of normal and gastric cancer subjects. The expression of complement component C9 protein was validated to be significantly higher in the plasma of gastric cancer compared to normal subjects. This was independent of the gastritis and H. pylori status of the patients. We also observed a statistically significant difference (p<0.04) in the expression level of C9 between patients with intestinal and diffuse types of cancer. Two independent blind test studies showed a high sensitivity and specificity to detect gastric cancer. The C9 protein is a biomarker for screening gastric cancer.
(FR)
Cette invention concerne le cancer de l'estomac, l'une des premières causes de décès par cancer au monde. Jusqu'ici il n'existait aucun marqueur spécifique pour dépister le cancer de l'estomac. Le profil d'expression de 37 protéines plasmatiques était constamment différent entre les sujets normaux et les sujets atteints du cancer de l'estomac. L'expression de la protéine plasmatique C9 du complément était significativement supérieure chez les sujets atteints du cancer de l'estomac que chez les sujets normaux. Ce résultat était indépendant du statut de gastrite et de H. pylori des patients. Des données ont aussi montré une différence statistiquement significative (p < 0,04) du taux d'expression de C9 entre les patients atteints du cancer de forme intestinale et de forme diffuse. Deux études indépendantes menées en aveugle ont montré une forte sensibilité et une forte spécificité pour détecter le cancer de l'estomac. La protéine C9 est un biomarqueur du dépistage du cancer de l'estomac.
Latest bibliographic data on file with the International Bureau